SEC Form S-1 filed by NeuroBo Pharmaceuticals Inc.
SECURITIES AND EXCHANGE COMMISSION
UNDER
THE SECURITIES ACT OF 1933
|
Delaware
(State or other jurisdiction of incorporation or organization) |
| |
2834
(Primary Standard Industrial Classification Code Number) |
| |
47-2389984
(IRS Employer Identification Number) |
|
Cambridge, Massachusetts 02138
(857) 702-9600
President, Chief Executive Officer and Director
545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
(857) 702-9600
Joshua W. Damm, Esq.
Samuel Katz, Esq.
Honigman LLP
65 Trade Centre Way, Suite 200
Kalamazoo, Michigan 49002
Tel: (269) 337-7700
Fax: (269) 337-7703
|
Large accelerated filer
|
| | ☐ | | | Accelerated filer | | | ☐ | |
|
Non-accelerated filer
|
| | ☒ | | |
Smaller reporting company
|
| | ☒ | |
| | | | | | |
Emerging growth company
|
| | ☐ | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 18 | | | |
| | | | 23 | | | |
EXPERTS | | | | | 24 | | |
| | | | 25 | | | |
| | | | 26 | | |
Name of Selling Securityholder
|
| |
Number of shares of
common stock beneficially owned prior to the offering |
| |
Maximum number of
shares of common stock to be sold pursuant to this prospectus |
| |
Number of shares of
common stock beneficially owned after the offering |
| |
Percentage of shares of
common stock beneficially owned after the offering (%) |
| ||||||||||||
Armistice Capital, LLC(1)
|
| | | | 690,829 | | | | | | 8,142,497 | | | | | | 690,829 | | | | | | 3.0 | | |
Dong-A ST Co., Ltd.(2)
|
| | | | 5,348,199 | | | | | | 8,905,855 | | | | | | 2,803,699 | | | | | | 12.3 | | |
Noam Rubinstein(3)
|
| | | | 40,127 | | | | | | 40,077 | | | | | | 50 | | | | | | * | | |
Craig Schwabe(4)
|
| | | | 4,300 | | | | | | 4,294 | | | | | | 6 | | | | | | * | | |
Michael Vasinkevich(5)
|
| | | | 81,685 | | | | | | 81,584 | | | | | | 101 | | | | | | * | | |
Charles Worthman(6)
|
| | | | 1,274 | | | | | | 1,272 | | | | | | 2 | | | | | | * | | |
| | |
Shares
Beneficially Owned |
| | | | | | | |||
Name Of Beneficial Owner
|
| |
Number
|
| |
Percent
|
| ||||||
Greater than 5% securityholders | | | | | | | | | | | | | |
Armistice Capital, LLC(1)
|
| | | | 690,829 | | | | | | 8.4% | | |
Dong-A ST Co., Ltd.(2)
|
| | | | 5,348,199 | | | | | | 65.1% | | |
Executive Officers and Directors | | | | | | | | | | | | | |
Mark A. Glickman(3)
|
| | | | 3,125 | | | | | | * | | |
Jason L. Groves(4)
|
| | | | 7,364 | | | | | | * | | |
Andrew Koven(5)
|
| | | | 7,365 | | | | | | * | | |
Hyung Heon Kim(6)
|
| | | | 83 | | | | | | * | | |
Michael Salsbury(7)
|
| | | | 7,364 | | | | | | * | | |
D. Gordon Strickland(8)
|
| | | | 7,256 | | | | | | * | | |
James P. Tursi(9)
|
| | | | 2,458 | | | | | | * | | |
Marshall Woodworth
|
| | | | — | | | | | | * | | |
All current executive officers and directors as a group (8 persons)
|
| | | | 35,015 | | | | | | * | | |
Item
|
| |
Amount Paid or
to Be Paid |
| |||
SEC registration fee
|
| | | $ | 11,902.37 | | |
FINRA filing fee
|
| | | | * | | |
Printing expenses
|
| | | | * | | |
Legal fees and expenses
|
| | | | * | | |
Accounting fees and expenses
|
| | | | * | | |
Transfer agent fees and expenses
|
| | | | * | | |
Miscellaneous fees and expenses
|
| | | | * | | |
Total
|
| | | $ | * | | |
President, Chief Executive Officer and Director
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Hyung Heon Kim
Hyung Heon Kim
|
| |
President, Chief Executive Officer and Director
(Principal Executive Officer) |
| |
July 18, 2024
|
|
|
/s/ Marshall H. Woodworth
Marshall H. Woodworth
|
| |
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer) |
| |
July 18, 2024
|
|
|
/s/ Andrew I. Koven
Andrew I. Koven
|
| |
Chairman of the Board
|
| |
July 18, 2024
|
|
|
/s/ Mark A. Glickman
Mark A. Glickman
|
| |
Director
|
| |
July 18, 2024
|
|
|
/s/ Jason L. Groves
Jason L. Groves
|
| |
Director
|
| |
July 18, 2024
|
|
|
/s/ Michael Salsbury
Michael Salsbury
|
| |
Director
|
| |
July 18, 2024
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ D. Gordon Strickland
D. Gordon Strickland
|
| |
Director
|
| |
July 18, 2024
|
|
|
/s/ James P. Tursi
James P. Tursi, M.D.
|
| |
Director
|
| |
July 18, 2024
|
|